Abstract
The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.
Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage
Current Drug Therapy
Title:Complications of Anti-Vascular Endothelial Growth Factor Drugs
Volume: 7 Issue: 2
Author(s): Michael Tolentino
Affiliation:
Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage
Abstract: The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.
Export Options
About this article
Cite this article as:
Tolentino Michael, Complications of Anti-Vascular Endothelial Growth Factor Drugs, Current Drug Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157488512800675959
DOI https://dx.doi.org/10.2174/157488512800675959 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mediterranean Diet And Longevity: An Example Of Nutraceuticals?
Current Vascular Pharmacology Halogen Dance Reaction and its Application in Organic Synthesis
Current Organic Chemistry Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Adherence to Cardiac Practice Guidelines in the Management of Non-ST-Elevation Acute Coronary Syndromes: A Systematic Literature Review
Current Cardiology Reviews Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Current Topics in Medicinal Chemistry Recent Advances in Developing Ophthalmic Formulations: A Patent Review
Recent Patents on Drug Delivery & Formulation The Burden of Cardiovascular Disease Risk Factors in the Middle East: A Systematic Review and Meta-Analysis Focusing on Primary Prevention
Current Vascular Pharmacology Cyclosporin A: A Therapeutic Strategy in Allergic Diseases
Letters in Drug Design & Discovery Dietary Approaches and Alternative Therapies for Polycystic Ovary Syndrome
Current Nutrition & Food Science Dyslipidemia, Metabolic Syndrome and Vascular Disease Among Asian Indians
Vascular Disease Prevention (Discontinued) New Perspectives in the Treatment of Cushings Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Effects of PPARγ Agonists against Vascular and Renal Dysfunction
Current Molecular Pharmacology Targeting Angiogenesis in Rheumatoid Arthritis
Current Rheumatology Reviews Editorial (Thematic Issue: Therapeutic Applications of Advanced Drug Delivery Systems)
Current Pharmaceutical Design Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets